Cited by 253Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphismsCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

Open access

Tenenbaum, Alexander, Motro, Michael, Fisman, Enrique Z·2005·Cardiovascular Diabetology

DOI 10.1186/1475-2840-4-14PMC PMC1236941

Open this paper in CoChat — free account Open PDF

Abstract

There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (HDL) cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. PPAR gamma activation results in insulin sensitization and antidiabetic action. Until recently, the biological role of PPAR beta/delta remained unclear. However, treatment of obese animals by specific PPAR delta agonists results in normalization of metabolic parameters and reduction of adiposity. Combined treatments with PPAR gamma and alpha agonists may potentially improve insulin resistance and alleviate atherogenic dyslipidemia, whereas PPAR delta properties may prevent the development of overweight which typically accompanies "pure" PPAR gamma ligands. The new generation of dual-action PPARs – the glitazars, which target PPAR-gamma and PPAR-alpha (like muraglitazar and tesaglitazar) are on deck in late-stage clinical trials and may be effective in reducing cardiovascular risk, but their long-term clinical effects are still unknown. A number of glitazars have presented problems at a late stage of clinical trials because of serious side-effects (including ragaglitazar and farglitazar). The old and well known lipid-lowering fibric acid derivative bezafibrate is the first clinically tested pan – (alpha, beta/delta, gamma) PPAR activator. It is the only pan-PPAR activator with more than a quarter of a century of therapeutic experience with a good safety profile. Therefore, bezafibrate could be considered (indeed, as a "post hoc" understanding) as an "archetype" of a clinically tested pan-PPAR ligand. Bezafibrate leads to considerable raising of HDL cholesterol and reduces triglycerides, improves insulin sensitivity and reduces blood glucose level, significantly lowering the incidence of cardiovascular events and new diabetes in patients with features of metabolic syndrome. Clinical evidences obtained from bezafibrate-based studies strongly support the concept of pan-PPAR therapeutic approach to conditions which comprise the metabolic syndrome. However, from a biochemical point of view, bezafibrate is a PPAR ligand with a relatively low potency. More powerful new compounds with pan-PPAR activity and proven long-term safety should be highly effective in a clinical setting of patients with coexisting relevant lipid and glucose metabolism disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/1475-2840-4-14

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study
(2000) · Circulation · doi:10.1161/01.cir.102.1.21 · Cited by 1,273
Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay
Krey, G. D., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., & Wahli, W. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.0007 · Cited by 1,230
PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 716
An overview on biological mechanisms of PPARs
Kota, B. P., Huang, T. H.-W., & Roufogalis, B. D. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 681
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646
PPARγ, the ultimate thrifty gene
Auwerx, J. (1999) · Diabetologia · doi:10.1007/s001250051268 · Cited by 612
Medical significance of peroxisome proliferator-activated receptors
Vamecq, J., & Latruffe, N. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10364-1 · Cited by 467
Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
Tenenbaum, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1154 · Cited by 307
Self-citation

Show all 44 references

Research works printed but not linked: 1

Goldfarb B: PPAR benefits beyond glucose control. Cardiovascular effects may be even greater with next generation. DOC News. 2005, 2: 14.

Sorted by citations

International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J. H., Berger, J. P., Chatterjee, K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,022
Mitochondrial dysfunction in diabetic kidney disease
Forbes, J. M., & Thorburn, D. R. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.9 · Cited by 650
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy‐Wenzig, E., Blunder, M., Liu, X., Malainer, C., Blažević, T., Schwaiger, S., Rollinger, J. M., Heiß, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 617
Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications
Mirza, A. Z., Althagafi, I. I., & Shamshad, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.067 · Cited by 563
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 540
Treatment of non-alcoholic fatty liver disease
Adams, L. A., & Angulo, P. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.042200 · Cited by 350
RETRACTED: Activation of the PPAR/PGC-1α Pathway Prevents a Bioenergetic Deficit and Effectively Improves a Mitochondrial Myopathy Phenotype
Wenz, T., Diaz, F., Spiegelman, B. M., & Moraes, C. T. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.006 · Cited by 297
Retracted
Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 307
In Vivo Correction of COX Deficiency by Activation of the AMPK/PGC-1α Axis
Viscomi, C. F., Bottani, E., Civiletto, G., Cerutti, R., Moggio, M. G., Fagiolari, G., Schon, E. A., Lamperti, C., & Zeviani, M. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.04.011 · Cited by 302
Mitochondrial Quality Control as a Therapeutic Target
Suliman, H. B., & Piantadosi, C. A. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.011502 · Cited by 267
Mechanisms Mediating the Regulation of Peroxisomal Fatty Acid Beta-Oxidation by PPARα
Tahri-Joutey, M., Andreoletti, P., Surapureddi, S., Nasser, B., Cherkaoui‐Malki, M., & Latruffe, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168969 · Cited by 273
Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Uittenbogaard, M. N., & Chiaramello, A. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140305224906 · Cited by 246
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
Impact of obesity on cardiovascular disease
Zalesin, K. C., Franklin, B. A., Miller, W. M., Peterson, E. D., & McCullough, P. A. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.005 · Cited by 231
PPAR dual agonists: Are they opening Pandora's Box?
Balakumar, P., ROSE, M., Ganti, S. S., Krishan, P., & Singh, M. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.03.002 · Cited by 192
PPAR agonists: multimodal drugs for the treatment of type-2 diabetes
Gross, B. S., & Staels, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.004 · Cited by 189
Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
Souza-Mello, V. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1012 · Cited by 182
The importance of free fatty acids in the development of Type 2 diabetes
Wilding, J. P. H. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02186.x · Cited by 178
Preventive and Prophylactic Mechanisms of Action of Pomegranate Bioactive Constituents
Viladomiu, M., Hontecillas, R., Lu, P., & Bassaganya-Riera, J. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/789764 · Cited by 187
Cardiovascular disease and modifiable cardiometabolic risk factors
Cannon, C. P. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80025-1 · Cited by 178
The Role of Reactive Oxygen Species in the Life Cycle of the Mitochondrion
Venditti, P., & Meo, S. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062173 · Cited by 176
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-125 · Cited by 172
Self-citation
The role of various peroxisome proliferator‐activated receptors and their ligands in clinical practice
Derosa, G., Sahebkar, A., & Maffioli, P. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25804 · Cited by 167
Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease
Johri, A., Calingasan, N. Y., Hennessey, T., Sharma, A., Yang, L., Wille, E. J., Chandra, A., & Beal, M. F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr541 · Cited by 163
Impact of Obesity on Cardiovascular Disease
Zalesin, K. C., Franklin, B. A., Miller, W. M., Peterson, E. D., & McCullough, P. A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.06.004 · Cited by 157
Physiological functions of peroxisome proliferator-activated receptor β
Neels, J. G., & Grimaldi, P. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00027.2013 · Cited by 161
Insulin Resistance and Mitochondrial Dysfunction
González-Franquesa, A., & Patti, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55330-6_25 · Cited by 160
Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models
Komen, J. C., & Thorburn, D. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12413 · Cited by 149
Pomegranate: a fruit that ameliorates metabolic syndrome
Medjakovic, S., & Jungbauer, A. (2012) · Food & Function · doi:10.1039/c2fo30034f · Cited by 148
Activation of Peroxisome Proliferator-Activated Receptor Pathway Stimulates the Mitochondrial Respiratory Chain and Can Correct Deficiencies in Patients’ Cells Lacking Its Components
Bastin, J., Aubey, F., Rötig, A., Münnich, A., & Djouadi, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1701 · Cited by 148
Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice
Rachid, T. L., Penna‐de‐Carvalho, A., Bringhenti, I., Águila, M. B., Mandarim‐de‐Lacerda, C. A., & Souza‐Mello, V. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.12.027 · Cited by 143
Peroxisome proliferator-activated receptors, Metabolic Syndrome and Cardiovascular Disease
Azhar, S. (2010) · Future Cardiology · doi:10.2217/fca.10.86 · Cited by 146
The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
Kaul, U., Parmar, D., Manjunath, K., Shah, M., Parmar, K., Patil, K. P., & Jaiswal, A. D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0884-3 · Cited by 134
The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation
Iannotti, F. A., & Vitale, R. M. (2021) · Cells · doi:10.3390/cells10030586 · Cited by 130
Current issues regarding treatment of mitochondrial fatty acid oxidation disorders
Spiekerkoetter, U., Bastin, J., Gillingham, M. B., Morris, A. A. M., Wijburg, F. A., & Wilcken, B. M. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9188-1 · Cited by 128
Long-Term Follow-Up of Bezafibrate Treatment in Patients With the Myopathic Form of Carnitine Palmitoyltransferase 2 Deficiency
Bonnefont, J., Bastin, J., Laforêt, P., Aubey, F., Mogenet, A., Romano, S., Ricquier, D., Gobin, S., Vassault, A. J., Béhin, A., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.55 · Cited by 127
Bezafibrate for an Inborn Mitochondrial Beta-Oxidation Defect
Bonnefont, J., Bastin, J., Béhin, A., & Djouadi, F. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0806334 · Cited by 122
Pharmacological advances in mitochondrial therapy
Singh, A., Faccenda, D., & Campanella, M. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103244 · Cited by 128
PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle
Hondares, E., Pineda-Torra, I., Iglesias, R., Staels, B., Villarroya, F., & Giralt, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.092 · Cited by 120
The role of PGC‐1 coactivators in aging skeletal muscle and heart
Dillon, L. M., Rebelo, A. P., & Moraes, C. T. (2012) · IUBMB Life · doi:10.1002/iub.608 · Cited by 116
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance
Grundy, S. M. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80005-0 · Cited by 116
The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD
Dixon, E. D., Nardo, A. D., Claudel, T., & Trauner, M. (2021) · Genes · doi:10.3390/genes12050645 · Cited by 118
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 108
Self-citation
Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation
Loving, B. A., Tang, M., Neal, M. C., Gorkhali, S., Murphy, R., Eckel, R. H., & Bruce, K. D. (2021) · Cells · doi:10.3390/cells10020198 · Cited by 105
“It is well-known that rosiglitazone is a selective agonist of PPARγ, while bezafibrate is a pan-PPAR agonist [52].”
Background
Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets
Cui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00321-3 · Cited by 126
PPARs and the kidney in metabolic syndrome
Ruan, X. Z., Zheng, F., & Guan, Y. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00152.2007 · Cited by 103
Suppression mechanisms of COX assembly defects in yeast and human: Insights into the COX assembly process
Barrientos, A., Gouget, K., Horn, D., Soto, I. C., & Fontanesi, F. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.05.003 · Cited by 99
Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice
Hsu, W.-H., Chen, T.-H., Lee, B., Hsu, Y.-W., & Pan, T. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.11.015 · Cited by 100
Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric Disorders
Nierenberg, A. A., Ghaznavi, S., Mathias, I. S., Ellard, K. K., JANOS, J. A., & Sylvia, L. G. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.12.014 · Cited by 97
Sodium Intake Regulates Glucose Homeostasis through the PPARδ/Adiponectin-Mediated SGLT2 Pathway
Zhao, Y., Gao, P., Sun, F., Li, Q., Chen, J., Yu, H., Li, L., Wei, X., He, H., Lu, Z., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.019 · Cited by 100
7-Hydroxy-benzopyran-4-one Derivatives: A Novel Pharmacophore of Peroxisome Proliferator-Activated Receptor α and -γ (PPARα and γ) Dual Agonists
Matin, A., Gavande, N. S., Kim, M. S., Yang, N. X., Salam, N. K., Hanrahan, J. R., Roubin, R. H., & Hibbs, D. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900964r · Cited by 93
BioGPS: Navigating biological space to predict polypharmacology, off-targeting, and selectivity
Siragusa, L., Cross, S., Baroni, M., Goracci, L., & Cruciani, G. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24753 · Cited by 92
Restoring the infected powerhouse: Mitochondrial quality control in sepsis
Chavez, F. L., Gartzke, L. P., van Beuningen, F. E., Wink, S. E., Henning, R. H., Krenning, G., & Bouma, H. R. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102968 · Cited by 99
Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Zardi, E. M., Navarini, L., Sambataro, G., Piccinni, P., Sambataro, F., Spina, C., & Dobrina, A. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990136 · Cited by 92
Peroxisome Proliferators‐Activated Receptor (PPAR) Modulators and Metabolic Disorders
Cho, M.-C., Lee, K., Paik, S., & Yoon, D. (2008) · PPAR Research · doi:10.1155/2008/679137 · Cited by 91
Peroxisome Proliferator-Activated Receptors-Alpha and Gamma Are Targets to Treat Offspring from Maternal Diet-Induced Obesity in Mice
Magliano, D. C., Bargut, T. C. L., de Carvalho, S. N., Águila, M. B., Mandarim‐de‐Lacerda, C. A., & Souza‐Mello, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064258 · Cited by 89
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
Tenenbaum, A., Fisman, E. Z., Motro, M., & Adler, Y. (2006) · Cardiovascular Diabetology · doi:10.1186/1475-2840-5-20 · Cited by 90
Self-citation
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 84
Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice
Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N. N., Calingasan, N. Y., Yang, L., Tampellini, D., Starkov, A. A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds355 · Cited by 78
Genetic Basis for Correction of Very-Long-Chain Acyl–Coenzyme A Dehydrogenase Deficiency by Bezafibrate in Patient Fibroblasts: Toward a Genotype-Based Therapy
Gobin, S., Djouadi, F., Aubey, F., Olpin, S. E., Andresen, B. S., Yamaguchi, S., Mandel, H., Fukao, T., Ruiter, J. P. N., Wanders, R. J. A., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/522375 · Cited by 78
PPARs Link Early Life Nutritional Insults to Later Programmed Hypertension and Metabolic Syndrome
Tain, Y., Hsu, C., & Chan, J. Y. H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010020 · Cited by 75
Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice
Li, F., Luo, H., Xu, Z., Yang, Z., Du, G., Zhang, Y., Yu, L., Hu, K., Zhu, W., Tong, Q., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3912-9 · Cited by 72
Pharmacophore modeling and parallel screening for PPAR ligands
Markt, P., Schuster, D., Kirchmair, J., Laggner, C., & Langer, T. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9140-0 · Cited by 71
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
Ji, L., Song, W., Fang, H., Li, W. S., Geng, J., Wang, Y., Guo, L., Cai, H., Yang, T., Li, H., et al. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.03.019 · Cited by 67
Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures
Oyama, T., Toyota, K., Waku, T., Hirakawa, Y., Nagasawa, N., Kasuga, J.-I., Hashimoto, Y., Miyachi, H., & Morikawa, K. (2009) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909015935 · Cited by 71
The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
Friedland, S. N., Leong, A., Filion, K. B., Genest, J. J., Lega, I. C., Mottillo, S., Poirier, P., Reoch, J., & Eisenberg, M. J. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.025 · Cited by 67
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis.
Giaginis, C., Giagini, A., & Theocharis, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.005 · Cited by 62
FIELDS of dreams, fields of tears: a perspective on the fibrate trials
Wierzbicki, A. S. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00882.x · Cited by 64
Diabetic cardiomyopathy: signaling defects and therapeutic approaches
Dobrin, J. S., & Lebeche, D. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.17 · Cited by 63
Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
Jani, R. H., Kansagra, K., Jain, M. R., & Patel, H. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0128-3 · Cited by 61
Structural Insights into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding
Batista, F. A. H., Trivella, D. B. B., Bernardes, A., Gratieri, J., de Oliveira, P. S. L., Figueira, A. C. M., Webb, P., & Polikarpov, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033643 · Cited by 61
Thermogenic and metabolic antiobesity drugs: rationale and opportunities
Clapham, J. C., & Arch, J. R. S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00608.x · Cited by 60
Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Mal, S., Dwivedi, A. R., Kumar, V., Kumar, N., Kumar, B., & Kumar, V. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200716113136 · Cited by 67
Noncoding Variants Connect Enhancer Dysregulation with Nuclear Receptor Signaling in Hematopoietic Malignancies
Li, K., Zhang, Y., Liu, X., Liu, Y., Gu, Z., Cao, H., Dickerson, K. E., Chen, M., Chen, W., Shao, Z., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1128 · Cited by 61
Effects of Fibrate Drugs on Expression of ABCA1 and HDL Biogenesis in Hepatocytes
Hossain, M. A., Tsujita, M., Gonzalez, F. J., & Yokoyama, S. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181624b22 · Cited by 58
Peroxisome proliferator-activated receptor-δ, a regulator of oxidative capacity, fuel switching and cholesterol transport
Fürnsinn, C., Willson, T. M., & Brunmair, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0492-0 · Cited by 56
Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani, O. A. B. S. M. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-6 · Cited by 55
Peroxisome proliferator‐activated receptors (PPARs) in the control of bone metabolism
Giaginis, C., Tsantili‐Kakoulidou, A., & Theocharis, S. E. (2007) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00486.x · Cited by 54
Prediabetes as a Therapeutic Target
Pour, O. R., & Dagogo-Jack, S. E. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.149096 · Cited by 55
Pharmacological and non-pharmacological interventions to influence adipose tissue function
Westerink, J., & Visseren, F. L. J. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-13 · Cited by 54
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease
Fisman, E. Z., & Tenenbaum, A. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-38 · Cited by 52
Self-citation
The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome
Huang, T. H.-W., Teoh, A. W., Beilun, L., Lin, D. S.-H., & Roufogalis, B. D. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.03.020 · Cited by 52
Sweroside ameliorates NAFLD in high-fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response
Yang, Q., Shu, F., Gong, J., Ding, P., Cheng, R., Li, J., Tong, R., Ding, L., Sun, H., Huang, W., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112556 · Cited by 51
The Role of PPARs in Breast Cancer
Zhao, B., Xin, Z., Ren, P., & Wu, H. (2022) · Cells · doi:10.3390/cells12010130 · Cited by 53
Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes
Massaro, M., Scoditti, E., Pellegrino, M., Carluccio, M. A., Calabriso, N., Wabitsch, M., Storelli, C., Wright, M. B., & Caterina, R. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.027 · Cited by 50
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)
Jia, W., Ma, J., Miao, H., Wang, C., Wang, X., Li, Q., Lu, W., Yang, J., Zhang, L., Yang, J., et al. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.02.027 · Cited by 49
Legumes as Functional Food for Cardiovascular Disease
Angeles, J. G. C., Villanueva, J. C., Uy, L. Y., Mercado, S. M. Q., Tsuchiya, M. C., Lado, J. P., Angelia, M. R. N., Bercansil, M. C. M. L., Estacio, M. A. C., & Torio, M. A. O. (2021) · Applied Sciences · doi:10.3390/app11125475 · Cited by 51
Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease
Wagner, N., & Wagner, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032345 · Cited by 48
Present and future therapeutic strategies in non-alcoholic fatty liver disease
Calamita, G., & Portincasa, P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1231 · Cited by 47
Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia
Waskowicz, L. R., Zhou, J., Landau, D. J., Brooks, E. D., Lim, A. R., Yavarow, Z. A., Kudo, T., Zhang, H., Wu, Y., Grant, S., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy343 · Cited by 47
RETRACTED: Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy
Noe, N., Dillon, L. M., Lellek, V., Díaz, F., Hida, A., Moraes, C. T., & Wenz, T. (2012) · Mitochondrion · doi:10.1016/j.mito.2012.12.003 · Cited by 49
Retracted
Cancer Chemopreventive Ability of Conjugated Linolenic Acids
Tanaka, T., Hosokawa, M., Yasui, Y., Ishigamori, R., & Miyashita, K. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12117495 · Cited by 46
PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders
Djouadi, F., & Bastin, J. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0844-7 · Cited by 46
Beneficial Health Effects of Chios Gum Mastic and Peroxisome Proliferator-Activated Receptors: Indications of Common Mechanisms
Georgiadis, I., Karatzas, T., Κορού, Λ.-Μ., Katsilambros, N. L., & Perrea, D. N. (2014) · Journal of Medicinal Food · doi:10.1089/jmf.2014.0021 · Cited by 46
Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-γ Agonist: A Single- and Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects
Kim, J., Kim, J., Yi, S., Shin, K.-H., Shin, H.-S., Yoon, S. H., Cho, J., Kim, D.-H., Shin, S., Jang, I., et al. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.023 · Cited by 45
Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study
Noguchi, T., Kobayashi, J., Yagi, K., Nohara, A., Yamaaki, N., Sugihara, M., Ito, N., Oka, R., Kawashiri, M., Tada, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.012 · Cited by 47
Myopathy caused by mammalian target of rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function
Romanino, K., Mazelin, L., Albert, V., Conjard‐Duplany, A., Lin, S., Bentzinger, C. F., Handschin, C., Puigserver, P., Zorzato, F., Schaeffer, L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111448109 · Cited by 44
Long-Term Bezafibrate Treatment Improves Skin and Spleen Phenotypes of the mtDNA Mutator Mouse
Dillon, L. M., Hida, A., García, S., Prolla, T. A., & Moraes, C. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044335 · Cited by 44
Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice
Barbosa‐da‐Silva, S., Souza‐Mello, V., Magliano, D. C., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.02.003 · Cited by 44

Authors: Tenenbaum, A., Motro, M., & Fisman, E. Z.
Affiliations: Sheba Medical Center (IL)
Tel Aviv University (IL)
Corresponding author: Tenenbaum, Alexander
ORCID: Tenenbaum, Alexander
Fisman, Enrique Z
Venue: Cardiovascular Diabetology
Publisher: Springer Science and Business Media LLC
Published: 2005-09-16
Volume: 4
Issue: 1
Pages: 14-14
ISSN: 1475-2840 (ISSN-L)
DOI: 10.1186/1475-2840-4-14
PMC: PMC1236941
OpenAlex: W2137116210
Cited by: 246
References: 44
Citations by year: 2026: 3 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 12 · 2021: 12 · 2020: 12 · 2019: 8 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 12 · 2014: 9 · 2013: 11 · 2012: 24
FWCI: 1.64
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Cardiovascular Diabetology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: bezafibrate, peroxisome proliferator-activated receptors, PPARα, PPARγ, PPARδ, metabolic syndrome, HDL cholesterol, triglycerides, insulin sensitivity, cardiovascular risk, fibrates, drug safety
MeSH terms: Hypolipidemic Agents, Bezafibrate, Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Cholesterol, HDL, Male, Middle Aged, Myocardial Infarction, Triglycerides, Peroxisome Proliferator-Activated Receptors, PPAR alpha, PPAR delta, PPAR gamma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks